Side Effects of Peptides: What We Know and What We Don't

Important: This article is exclusively for educational and informational purposes. Research peptides are not approved for human use. It does not constitute medical advice. For any use, consult a qualified medical professional.

Peptides are attracting enormous interest — and rightly so. But "popular" doesn't mean "safe." The safety of each peptide depends on the level of clinical evidence — and the difference between approved drugs and research-grade peptides is enormous.

In this article, we look at the side effects of the most popular peptides, divided by their level of clinical evidence.

Levels of clinical evidence

Before the specific data, it's important to understand the grading:

| Level | Description | Reliability |
|---|---|---|
| Phase 3 RCT | Randomized controlled trials with thousands of participants | Very high |
| Phase 2 RCT | Smaller clinical trials (50-200 participants) | High |
| Phase 1 | Safety/dosage in small groups | Medium |
| Preclinical | Animal models (mice, rats, dogs) | Low for humans |
| Case reports | Individual cases, not controlled | Anecdotal |

GLP-1 receptor agonists (Semaglutide, Tirzepatide)

Level of evidence: Phase 3 RCT (highest)

Semaglutide has been studied in over 35,000 participants in Phase 3 programs (SUSTAIN, PIONEER, STEP). Its safety profile is the best documented among all peptides.

Common side effects (>10% of patients):

• Nausea (nausea) — the most common, dose-dependent, usually resolves within 4-8 weeks
• Diarrhea — short-term
• Vomiting — less common, but reported
• Constipation — variable

Less common (1-10%):

• Headache
• Nasopharyngitis
• Abdominal pain
• Injection site reaction

Rare but serious:

• Pancreatitis — very rare, but monitored
• Gallstone disease — increased risk with rapid weight loss
• Mental health changes (suicidality) — FDA monitoring ongoing

An important nuance regarding compounded GLP-1

A recent pharmacovigilance study (2025) in the FDA Adverse Event Reporting System found that compounded GLP-1 agonists (non-patented pharmacy formulations) have a higher likelihood of abdominal pain, nausea, diarrhea, and biliary inflammation compared to standard formulations.

BPC-157

Level of evidence: Preclinical (+ 1 pilot human study)

BPC-157 has been studied primarily in animal models. A 2025 pilot study on intravenous infusion showed preliminary tolerability, but with a limited number of participants.

Preclinical data (animal):

• BPC-157 has been administered to rodents at doses 100-1000× higher than typical research doses for extended periods — with no evidence of toxicity, genotoxicity, carcinogenicity, or organ damage

Reported in human research contexts (informal):

• Discomfort at the injection site
• Dizziness
• Changes in GI function
• Vivid dreams or altered sleep

FDA position:

The FDA classifies BPC-157 as a Category 2 bulk drug substance. The agency notes potential immunogenic risk and a lack of adequate safety-related information in humans.

TB-500 (Thymosin β-4)

Level of evidence: Phase 2 (clinical evidence for skin ulcers)

TB-500 has better clinical evidence than BPC-157 — Phase 2 clinical trials for stasis and pressure ulcers have been conducted.

Preclinical data:

• No significant side effects in animal models
• Accelerated healing by 42-61%

Reported in clinical context:

• Generally well tolerated in Phase 2 trials
• Mild redness at the injection site

For a comparison of BPC-157 and TB-500 — see our detailed guide.

GHK-Cu (Copper tripeptide)

Level of evidence: Cosmetic use (approved), research for other applications

GHK-Cu has the safest profile among popular peptides, most likely because it is naturally present in human plasma.

Documented effects:

• Very rare allergic reaction (with topical application)
• Skin irritation at high concentrations
• Slight change in skin pigmentation (due to the copper complex)

Ipamorelin and CJC-1295

Level of evidence: Phase 1/2 (limited)

Reported in the research literature:

• Headache
• Water retention
• Changes in appetite
• Numbness/tingling (paresthesia)
• Increased drowsiness

General risks with research-grade peptides

Regardless of the specific peptide, research-grade products carry common risks:

1. Incomplete safety data

For most research peptides, we don't know the proper dose, the purity of contaminants, or the effects of long-term use. The lack of Phase 3 data means the safety profile is incomplete.

2. Product quality

The market is unregulated. A product with lower purity (<95%) may contain impurities with unpredictable effects. Therefore a Certificate of Analysis (CoA) with HPLC ≥98% is an absolute minimum. Read our guide to quality and CoA.

3. Immunogenicity

Exogenous peptides can trigger an immune response — formation of antibodies, which:

• Reduces effectiveness over time
• May trigger an allergic reaction
• Theoretical risk of an autoimmune response

4. Drug interactions

Most peptides have not been studied for drug-drug interactions. Combination with prescription drugs may be unpredictable.

Recommendations for a responsible approach

1. Consult a doctor — before any use
2. Check the CoA — purity ≥98% + MS confirmation → How to read a CoA
3. Know the level of evidence — Phase 3 approved ≠ research-grade with preclinical data
4. Don't mix — without proven protocols for combinations

Read our full peptide guide for more information on types, mechanisms, and quality standards.

Sources

1. Alkhouli M.F. et al. (2025). Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment. Pharmaceuticals.
2. Chen Z. et al. (2025). Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA AERS.
3. Cerovecki T. et al. (2025). Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.
4. Shrimanker I. et al. (2017). Adverse Effects of GLP-1 Receptor Agonists. StatPearls.
5. Malinda K.M. et al. (1999). Thymosin beta4 accelerates wound healing. JID.